Cybin Inc Q2 2026 Earnings Call: Strategic Advancements Amid Financial Challenges
AI Summary1 min read
TL;DR
Cybin Inc advanced Phase 2 and 3 studies, secured $175M financing, but faces financial losses and leadership changes. Top-line data for CYB004 is expected in Q1 2026.
Tags
Cybin
Cybin Inc has completed enrollment for its Phase 2 CYB004 study, progressing Phase 3 studies for CYB003, and secured a $175 million financing. However, the company faces financial challenges with increased cash-based operating expenses and a net loss of $33.7 million. Additionally, a leadership transition is underway, and there is competition for resources at clinical trial sites. The CYB004 study aims for directional data and dose response, with top-line data expected in Q1 2026.